Shares of Precigen PGEN have witnessed a sharp increase in the past three months, driven by growing investor optimism surrounding the strong commercial performance of the company’s sole marketed drug, Papzimeos (zopapogene imadenovec-drba), as well as broader pipeline progress.
Papzimeos is currently the first and only FDA-approved therapy for adults with recurrent respiratory papillomatosis (RRP). The product has demonstrated strong early commercial momentum since its approval and launch in 2025.
In the first six months of 2026, Papzimeos generated $74.6 million in revenues. Importantly, product revenues from Papzimeos sales more than doubled sequentially during the second quarter of 2026.
Precigen is also pursuing additional growth opportunities outside the United States. A marketing authorization application, seeking approval for Papzimeos to treat adults with RRP, is currently under review in Europe.
A potential approval in Europe could further boost the drug’s sales and drive revenues.
PGEN’s Price Performance
Shares of Precigen have surged 52.5% in the past three months against the industry’s decline of 0.2%.
Image Source: Zacks Investment Research
More on PGEN’s Papzimeos & Other Pipeline
The approval of Papzimeos transitioned Precigen from a development-stage to a commercial-stage company.
The sustained commercial momentum could support revenue growth for Precigen through the remainder of 2026. Sales are expected to grow steadily as Precigen expands its commercial footprint and strengthens its marketing infrastructure, driving continued momentum for Papzimeos.
Meanwhile, Papzimeos benefits from seven years of FDA market exclusivity through Aug. 14, 2032. Combined with its first-in-class position and lack of an approved competing therapy for adult RRP, this protection allows Precigen to establish a durable commercial franchise before potential competitors enter the market.
Inovio Pharmaceuticals INO is developing its lead candidate, INO-3107, a DNA-based immunotherapy as a treatment for RRP.
Inovio’s biologics license application seeking approval for INO-3107 in RRP is currently under review in the United States. A decision from the FDA is expected on Oct. 30, 2026.
Beyond Papzimeos, Precigen retains pipeline potential through its AdenoVerse platform. The company is developing PRGN-2009, an investigational AdenoVerse immunotherapy in HPV-driven cancers. The FDA recently granted platform technology designation to Precigen’s AdenoVerse immunotherapeutic platform.
A multicenter phase II study is evaluating PRGN-2009 in combination with Merck’s MRK blockbuster PD-L1 inhibitor, Keytruda (pembrolizumab), in patients with recurrent or metastatic cervical cancer.
Merck’s biggest revenue driver, Keytruda, is approved for several types of cancers globally.
Precigen plans to provide an update on the broader AdenoVerse portfolio, including PRGN-2009, by the end of 2026.
The company's recent developments and continued momentum in Papzimeos sales, along with encouraging pipeline progress, should continue the upward momentum for PGEN stock for the rest of 2026.
Precigen, Inc. Price
Precigen, Inc. price | Precigen, Inc. Quote
PGEN’s Zacks Rank
Precigen currently sports a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Zacks' Research Chief Names "Stock Most Likely to Double"
Our team of experts has just released the 5 stocks with the greatest probability of gaining +100% or more in the coming months. Of those 5, Director of Research Sheraz Mian highlights the one stock set to climb highest.
This innovative software-as-a-service firm upped its user base +22% year over year. That rate is increasing and margins are expanding as AI efficiencies take effect. Of course, all our elite picks aren't winners, but this one could far surpass earlier Zacks' Stocks Set to Double like D-Wave Quantum, which shot up +680.1%.
Free: See Our Top Stock And 4 Runners UpWant the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Precigen, Inc. (PGEN): Free Stock Analysis Report
Merck & Co., Inc. (MRK): Free Stock Analysis Report
Inovio Pharmaceuticals, Inc. (INO): Free Stock Analysis Report
This article originally published on Zacks Investment Research (zacks.com).